Sarah Cannon Research Institute | Strategic Alliance Partners

February 24, 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

February 24, 2018

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses the advancement of supportive care in hematologic malignancies.

February 23, 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

February 23, 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

February 14, 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

February 03, 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

January 30, 2018

Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.

January 06, 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

January 03, 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.

December 21, 2017

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

December 19, 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

November 28, 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

October 24, 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

July 12, 2017

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

July 07, 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

May 30, 2017

Susan Garwood, MD, discusses biopsy advancements and the future of techniques in lung cancer.

April 27, 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

April 26, 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).

April 22, 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

April 07, 2017

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.